Procalcitonin and Lung Ultrasonography Guided Antibiotherapy in Emergency Departments
Key facts
- Who runs it
- Dr Boillat-Blanco Noemie
- Where
- Switzerland9 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,407 people enrolled
- Started
- 5 Dec 2022
- Ended
- 11 Jun 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- The PLUS algorithm
- Usual care
- Record updated
- 24 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Signed informed consent
- Patients aged 18 years or more
- Acute LRTI (acute illness, less than 21 days, with at least one lower respiratory tract symptom, i.e. cough, sputum, dyspnea, chest pain and no alternative explanation)
- At least one of the following clinical criteria:; Focal abnormal auscultation (decreased breath sounds, crackles, bronchial breath sounds); Fever (documented temperature ≥ 38°C in the last 24 hours, including self-measured temperature ≥ 38°C); Tachypnea (respiratory rate ≥ 22/minute); Tachycardia (heart rate ≥ 100/minute)
Who cannot take part
- Previous receipt of a quinolone, macrolide or ceftriaxone or, of more than one dose of any other antibiotic within 72h prior to enrolment (excepted prophylactic antibiotics or antibiotics given for urinary tract infection)
- Previous hospital stay in the last 14 days
- Severe COPD (≥GOLD 3 or if not available, as a proxy: exacerbation treated with antibiotics during the last 6 months)
- Severe immunodeficiency (drug-induced neutropenia with <500 neutrophils/mm3, HIV infection with CD4<200 cells/mm3, solid organ or bone marrow transplant recipient, prednisone ≥ 20mg/day for >28 days)
- Cystic fibrosis
- Initial admission of the patient in the intensive care unit
- Microbiologically-documented SARS-CoV-2
- Incapacity of discernment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Acute respiratory infections are a common reason of attendance at emergency departments. It is also the main reason of unnecessary antibiotic prescription. Antibiotics save lives, but can also directly harm patients by causing antibiotic-associated adverse events. Antibiotic use is directly related to resistance, which is one of the major threats of our century. In addition, some microorganisms live in and on the human body and promote many aspects of our health. Antibiotic treatment can disturb those microorganisms and therefore have long-lasting negative effects on our health.
Read full original descriptionShow less
Unfortunately, it is difficult to differentiate between viral infections, which usually heal spontaneously, and bacterial pneumonia, which needs antibiotics treatment. This is one of the reasons of this over-prescribing of antibiotics.
This project aims to reduce widespread use of antibiotics in the emergency department through a new diagnostic strategy of bacterial pneumonia. This strategy includes sequential use of well-known techniques: a clinical score, lung ultrasound and finally a biomarker, procalcitonin. The latter tends to be higher in bacterial infections. The combination of these different tests improves the diagnostic process and allows improved use of targeted antibiotics, with the ultimate goal of better patient management.
The study will compare the antibiotic prescription rate and the clinical course of patients managed using this new diagnostic approach with those managed as usual. The project will also evaluate the acceptability and feasibility of this strategy and its cost-effectiveness. These two aspects are essential for a wider implementation of this innovative diagnostic approach and decrease antibiotic resistance.
The 2 groups in the trial
- The PLUS algorithmTreatment being tested
The PLUS clinical management algorithm: EDs having switched to the intervention period (intervention group) will manage their patients using the PLUS algorithm. The PLUS algorithm starts with a validated pneumonia clinical prediction score (score of Van Vugt), followed by LUS. In case of positive results of any of these tests, PCT is measured to identify patients who will most likely benefit from antibiotics. A validated clinical severity score will ensure the safety of the intervention in those with discordant results (LUS consolidation and low PCT).
- Usual careOther group
Usual care: management as usual
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Procalcitonin and Lung Ultrasonography Based Antibiotherapy in Patients With Lower Respiratory Tract Infection in Swiss Emergency Departments: Pragmatic Stepped-wedge Cluster-randomized Trial
- Publications
- Record updated
- 24 April 2026